1.. Introduction   {#sec1}
==================

Feline coronaviruses (FCoVs), which belong to the genus *Alphacoronavirus* of the subfamily *Coronavirinae*, are the leading pathogen of Felidae around the world (Horzinek & Osterhaus, 1979[@bb9]). FCoVs have two antigenically distinct serotypes: type I and type II (Balint, Farsang, Szeredi *et al.*, 2014[@bb4]). Both serotypes occur in two pathotypes: *Feline enteric coronavirus* (FECV) and *Feline infectious peritonitis virus* (FIPV). FECV mainly replicates in the lower portion of the intestinal tract, spreads by the faecal--oral route, and presents clinically as mild or inapparent enteritis (Pedersen *et al.*, 1981[@bb14]; Herrewegh *et al.*, 1997[@bb7]; Balint, Farsang, Zadori *et al.*, 2014[@bb5]). On the other hand, FIPV efficiently replicates in macrophages/monocytes, leading to feline infectious peritonitis (FIP), a highly lethal systemic granulomatous disease of wild and domestic cats (Addie *et al.*, 2009[@bb1]; Pedersen, 2009[@bb13]; Balint, Farsang, Szeredi *et al.*, 2014[@bb4]; Balint, Farsang, Zadori *et al.*, 2014[@bb5]; Kipar & Meli, 2014[@bb10]). FIP, as an immune-mediated disease, features the antibody-dependent enhancement (ADE) phenomenon (Weiss & Scott, 1981[@bb18]; Vennema *et al.*, 1990[@bb17]; Tirado & Yoon, 2003[@bb16]). The virus-specific antibodies induced upon infection by FIPV in cats do not protect them, but enhance the infection by FIPV and thus accelerate the disease symptoms (Weiss & Scott, 1981[@bb18]; Vennema *et al.*, 1990[@bb17]; Tirado & Yoon, 2003[@bb16]; Takano *et al.*, 2008[@bb15]). Hence, there has been little progress in the development of clinical vaccines against FIPV, although a variety of methods have been tried, such as avirulent vaccines, attenuated live FIPV vaccines and recombinant vaccines (Pedersen, 2009[@bb13]).

Like other coronaviruses, FIPV contains a single-stranded positive-sense polyadenylated RNA genome that encodes two large polyproteins (pp1a and pp1ab) which need to be processed into 16 non­structural proteins (nsp1--16) for genome replication (Dye & Siddell, 2005[@bb6]). This process is mediated by two virus-encoded proteinases. Nsp5, also named main protease (M^pro^), is responsible for 11 out of 15 cleavage sites, thus playing a pivotal role in this digestion process and being indispensable for viral replication (Dye & Siddell, 2005[@bb6]). The critical role of nsp5 in virus replication makes it an ideal target for anti-FIPV drug design (Yang *et al.*, 2005[@bb19]; Anand *et al.*, 2003[@bb3]). To date, several crystal structures of other coronavirus main proteases have been solved (Anand *et al.*, 2002[@bb2], 2003[@bb3]; Yang *et al.*, 2003[@bb20], 2005[@bb19]; Hilgenfeld, 2014[@bb8]). Based on the structural analysis of these main proteases, the idea of designing wide-spectrum inhibitors against CoVs has been proposed. In this study, we report the crystallization and preliminary crystallographic study of FIPV main protease in complex with a designed Michael acceptor inhibitor named N3 (Supplementary Fig. S1[1](#fn1){ref-type="fn"}).

2.. Materials and methods   {#sec2}
===========================

2.1.. Macromolecule production   {#sec2.1}
--------------------------------

The coding sequence for FIPV main protease was synthesized and was cloned into the vector pGEX-6P-1 using the *Bam*HI and *Xho*I restriction sites (Table 1[▶](#table1){ref-type="table"}). The recombinant plasmid was verified by sequencing and then transformed into *Escherichia coli* strain BL21 (DE3) for protein expression. Cultures were grown in LB medium containing 0.1 mg ml^−1^ ampicillin at 310 K until the optical density at 600 nm reached 0.6. Isopropyl β-[d]{.smallcaps}-1-thiogalactopyranoside was then added to a final concentration of 0.5 m*M* and the cultures were induced to express FIPV main protease at 289 K for 16 h. Thereafter, centrifugation was used to harvest the cells and the bacterial pellets were resuspended in PBS (140 m*M* NaCl, 10 m*M* Na~2~HPO~4~, 2.7 m*M* KCl, 1.8 m*M* KH~2~PO~4~ pH 7.3) supplemented with 1 m*M* dithiothreitol (DTT) and 10% glycerol. After sonication at 277 K, the bacterial lysate was centrifuged at 12 000*g* for 50 min at 277 K and the precipitate was discarded. The supernatant was loaded onto a disposable column containing glutathione Sepharose 4B affinity resin (Pharmacia) to purify the GST-tagged FIPV main protease. The fusion protein was then subjected to on-column cleavage using commercial PreScission protease (Pharmacia) at 277 K for 18 h. The protease was added to a final concentration of 0.25 mg ml^−1^ for proteolysis in PBS. Five additional residues (GPLGS) were left at the N-terminus of FIPV main protease. The resulting protein of interest was further purified by anion-exchange chromatography using a HiTrap Q column (GE Healthcare) with a linear gradient from 25 to 250 m*M* NaCl in 20 m*M* Tris--HCl pH 8.0, 10% glycerol, 1 m*M* DTT and reached more than 90% purity by SDS--PAGE analysis (Fig. 1[▶](#fig1){ref-type="fig"} *a*).

2.2.. Crystallization   {#sec2.2}
-----------------------

The purified protein was immediately supplemented with 10% DMSO and concentrated to 1 mg ml^−1^. The previously reported inhibitor N3 (Yang *et al.*, 2005[@bb19]), dissolved in 100% DMSO to a final concentration of 10 m*M* as a stock, was added to the purified protein to give a molar ratio of between 3:1 and 5:1. After mixing at 4°C for 4 h, the protein complex was centrifuged at 12 000*g* for 10 min and exchanged into a buffer consisting of 10 m*M* HEPES pH 7.5, 150 m*M* NaCl, 1 m*M* DTT using Thermo iCON concentrators. The final protein was concentrated to 8 mg ml^−1^ for crystallization. In the initial stage, commercial screening kits, including Crystal Screen, Crystal Screen 2, PEG/Ion and Index (Hampton Research, Laguna Niguel, California, USA), were used to screen for preliminary crystallization conditions for FIPV main protease with the inhibitor N3. Crystallization trials were set up in 16-well crystallization plates at 291 K using the hanging-drop vapour-diffusion method. Crystallization drops were carefully set up by mixing 1.0 µl protein solution with 1.0 µl reservoir solution and were then left to equilibrate against 200 µl reservoir solution. Initial crystals of FIPV main protease in complex with N3 inhibitor were obtained after 24 h under condition No. 45 from Crystal Screen, which consists of 0.2 *M* zinc acetate dihydrate, 0.1 *M* sodium cacodylate trihydrate pH 6.5, 18%(*w*/*v*) polyethylene glycol 8000. The optimized condition consisted of 0.2 *M* zinc acetate dihydrate, 0.1 *M* sodium cacodylate trihydrate pH 6.5, 14%(*w*/*v*) polyethylene glycol 8000 (Fig. 1[▶](#fig1){ref-type="fig"} *b*). The crystallization information is summarized in Table 2[▶](#table2){ref-type="table"}.

2.3.. X-ray data collection and processing   {#sec2.3}
--------------------------------------------

The crystals were cryoprotected in a solution consisting of 0.2 *M* zinc acetate dihydrate, 0.1 *M* sodium cacodylate trihydrate pH 6.5, 14%(*w*/*v*) polyethylene glycol 8000, 20% glycerol and were then mounted in a nylon loop and flash-cooled in a nitrogen stream at 100 K. Data were collected using an ADSC Q315r detector on beamline BL17U of the Shanghai Synchrotron Radiation Facility (SSRF) at a wavelength of 0.97923 Å. A complete data set was collected from a single crystal which diffracted to 2.5 Å resolution (Fig. 2[▶](#fig2){ref-type="fig"}). All intensity data were indexed, integrated and scaled with the *HKL*-2000 package (Otwinowski & Minor, 1997[@bb12]). The related data-collection and processing statistics are summarized in Table 3[▶](#table3){ref-type="table"}.

3.. Results and discussion   {#sec3}
============================

FIP, which is mainly caused by FIPV, is a lethal systemic granulomatous disease of cats around the world (Addie *et al.*, 2009[@bb1]; Pedersen, 2009[@bb13]; Balint, Farsang, Szeredi *et al.*, 2014[@bb4]; Balint, Farsang, Zadori *et al.*, 2014[@bb5]; Kipar & Meli, 2014[@bb10]). However, upon virus infection the induced antibodies further enhance the infection instead of neutralizing the virus. This is the so-called 'antibody-dependent enhancement' (Weiss & Scott, 1981[@bb18]; Vennema *et al.*, 1990[@bb17]; Tirado & Yoon, 2003[@bb16]). Thus, no clinical vaccines against FIPV have been successfully developed to date. For this reason, the FIPV main protease, which is indispensable for virus replication, is an alternative target for antiviral therapy and has been subjected to crystallographic studies.

FIPV main protease was expressed as a GST-tagged protein, digested using commercial PreScission protease (Pharmacia) and was then purified using anion-exchange chromatography on a HiTrap Q column. The final protein used for crystallization trials reached greater than 90% purity as monitored by SDS--PAGE. Crystals could be obtained from condition No. 45 of Crystal Screen. The optimized crystals diffracted to a highest resolution of 2.5 Å using 0.2 *M* zinc acetate dihydrate, 0.1 *M* sodium cacodylate trihydrate pH 6.5, 14%(*w*/*v*) polyethylene glycol 8000, 20% glycerol as a cryoprotectant. The crystal belonged to space group *I*422, with unit-cell parameters *a* = 112.3, *b* = 112.3, *c* = 102.1 Å. Based on the molecular weight of the monomer, the Matthews coefficient (Matthews, 1968[@bb11]) was calculated to be 2.43 Å^3^ Da^−1^ and the solvent content was 49.5%, assuming the presence of one molecule per asymmetric unit. Further structural and biochemical analysis of FIPV main protease in complex with the Michael acceptor N3 will lead to better design and optimization of antivirals against FIP.

Supplementary Material
======================

Chemical structure of the compound N3.. DOI: [10.1107/S2053230X14022390/no5064sup1.pdf](http://dx.doi.org/10.1107/S2053230X14022390/no5064sup1.pdf)

Supporting information has been deposited in the IUCr electronic archive (Reference: [NO5064](http://scripts.iucr.org/cgi-bin/sendsup?no5064sup1.pdf)).
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![Purification and crystallization of FIPV main protease. (*a*) SDS--PAGE analysis of purified FIPV main protease. The molecular masses of the marker and FIPV main protease are indicated in kDa. (*b*) Typical complex crystals of FIPV main protease with inhibitor N3 grown by the hanging-drop method. These crystals, with typical dimensions of 0.03 × 0.03 × 0.03 mm, were used for subsequent diffraction and data collection.](f-70-01612-fig1){#fig1}

![A typical diffraction pattern of an FIPV main protease complex crystal collected on beamline BL17U of the Shanghai Synchrotron Radiation Facility (SSRF). The edge of the frame is at 1.76 Å resolution. The box shows diffraction spots in the outer resolution shell.](f-70-01612-fig2){#fig2}

###### Macromolecule-production information

  -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Source organism                                          FIPV strain 791146 (GenBank accession No. AF326575)
  DNA source                                               Synthetic plasmid
  Forward primer[†](#tfn1){ref-type="table-fn"}            CG[GGATCC]{.ul}AGCGGTCTGCGTAAAATG
  Reverse primer[‡](#tfn2){ref-type="table-fn"}            CCG[CTCGAG]{.ul}TTACTGCAGATTAACGCCATAC
  Cloning vector                                           pGEX-6P-1
  Expression vector                                        pGEX-6P-1
  Expression host                                          *E. coli* BL21 (DE3)
  Complete amino-acid sequence of the construct produced   [GPLGS]{.ul}SGLRKMAQPSGVVEPCIVRVAYGNNVLNGLWLGDEVICPRHVIASDTSRVINYENELSSVRLHNFSIAKNNAFLGVVSAKYKGVNLVLKVNQVNPNTPEHKFKSVRPGESFNILACYEGCPGSVYGVNMRSQGTIKGSFIAGTCGSVGYVLENGTLYFVYMHHLELGNGSHVGSNLEGEMYGGYEDQPSMQLEGTNVMSSDNVVAFLYAALINGERWFVTNTSMTLESYNAWAKTNSFTEIVSTDAFNMLAAKTGYSVEKLLECIVRLNKGFGGRTILSYGSLCDEFTPTEVIRQMYGVNLQ
  -------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Underlined sequence: *Bam*HI site.

Underlined sequence: *Xho*I site.

###### Crystallization

  ---------------------------------------- ------------------------------------------------------------------------------------------------------------------
  Method                                   Hanging-drop vapour diffusion
  Plate type                               16-well crystallization plate
  Temperature (K)                          291
  Protein concentration (mgml^1^)          8
  Buffer composition of protein solution   10m*M* HEPES pH 7.5, 150m*M* NaCl, 1m*M* DTT
  Composition of reservoir solution        0.2*M* zinc acetate dihydrate, 0.1*M* sodium cacodylate trihydrate pH 6.5, 14%(*w*/*v*) polyethylene glycol 8000
  Volume and ratio of drop                 1.0l + 1.0l
  Volume of reservoir (l)                  200
  ---------------------------------------- ------------------------------------------------------------------------------------------------------------------

###### Data-collection and processing statistics

Values in parentheses are for the outer shell.

  ------------------------------------------------- ------------------------------------------
  Diffraction source                                Beamline BL17U, SSRF
  Wavelength ()                                     0.97923
  Temperature (K)                                   100
  Detector                                          ADSC Q315r
  Crystal-to-detector distance (mm)                 250
  Rotation range per image ()                       1
  Total rotation range ()                           95
  Space group                                       *I*422
  Unit-cell parameters (, )                         *a* = *b* = 112.3, *c* = 102.1, = = = 90
  Mosaicity ()                                      0.83
  Resolution range ()                               50.02.45 (2.492.45)
  Total No. of reflections                          89406 (4704)
  No. of unique reflections                         12082 (619)
  Completeness (%)                                  97.8 (99.4)
  Multiplicity                                      7.4 (7.6)
  *I*/(*I*)                                         44.1 (8.6)
  *R* ~merge~ [†](#tfn3){ref-type="table-fn"} (%)   7.0 (44.1)
  *R* ~meas~ [‡](#tfn4){ref-type="table-fn"} (%)    7.5 (47.3)
  ------------------------------------------------- ------------------------------------------

*R* ~merge~ = , where *I~i~*(*hkl*) is the intensity of the *i*th observation of reflection *hkl* and *I*(*hkl*) is the average intensity.

*R* ~meas~ is calculated by multiplying the *R* ~merge~ value by the factor \[*N*/(*N* 1)\]^1/2^.
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